Michael Lauseker

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann et al. · Leukemia · 2012 · 416 citations

Hematological Malignancy, Chronic Myeloid Leukemia, Health Sciences +10

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia

Rüdiger Hehlmann, Michael Lauseker, Susanne Jung-Munkwitz et al. · Journal of Clinical Oncology · 2011 · 321 citations · Full text

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

Rüdiger Hehlmann, Martin C. Müller, Michael Lauseker et al. · Journal of Clinical Oncology · 2013 · 296 citations · Full text

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

Alice Fabarius, Armin Leitner, Andreas Hochhaus et al. · Blood · 2011 · 286 citations

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

Lida Kalmanti, Michael Lauseker, M. C. Muller et al. · Leukemia · 2015 · 273 citations

Hematological Malignancy, Oncology, Clinical Trials +8